Cargando…
Estrogens Modulate Somatostatin Receptors Expression and Synergize With the Somatostatin Analog Pasireotide in Prostate Cells
Prostate cancer (PC) is one of the most frequently diagnosed cancers and a leading cause of cancer-related deaths in Western society. Current PC therapies prevalently target the functions of androgen receptor (AR) and may only be effective within short time periods, beyond which the majority of PC p...
Autores principales: | Rossi, Valentina, Di Zazzo, Erika, Galasso, Giovanni, De Rosa, Caterina, Abbondanza, Ciro, Sinisi, Antonio A., Altucci, Lucia, Migliaccio, Antimo, Castoria, Gabriella |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384260/ https://www.ncbi.nlm.nih.gov/pubmed/30828298 http://dx.doi.org/10.3389/fphar.2019.00028 |
Ejemplares similares
-
Prostate cancer stem cells: the role of androgen and estrogen receptors
por: Di Zazzo, Erika, et al.
Publicado: (2015) -
Estrogen Receptors in Epithelial-Mesenchymal Transition of Prostate Cancer
por: Di Zazzo, Erika, et al.
Publicado: (2019) -
Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
por: Gadelha, Mônica, et al.
Publicado: (2020) -
AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients
por: Daly, Adrian F, et al.
Publicado: (2019) -
Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression
por: Mizuno, Tomoko, et al.
Publicado: (2021)